Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AHCONASDAQ:CDNANASDAQ:PSNLNASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHCOAdaptHealth$8.30-1.1%$8.59$7.11▼$11.90$1.13B1.641.30 million shs1.24 million shsCDNACareDx$18.95-0.5%$17.57$13.81▼$34.84$1.06B2.18907,962 shs730,877 shsPSNLPersonalis$6.21-3.3%$4.76$1.14▼$7.20$567.05M1.861.07 million shs1.21 million shsVRDNViridian Therapeutics$14.71-0.1%$13.79$9.90▼$27.20$1.20B0.411.16 million shs536,543 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHCOAdaptHealth0.00%-2.44%-4.44%-19.25%-24.14%CDNACareDx0.00%+2.42%+12.33%-2.91%+35.42%PSNLPersonalis0.00%+6.82%+34.31%+67.19%+426.23%VRDNViridian Therapeutics0.00%-7.30%+8.47%-4.79%+17.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHCOAdaptHealth3.8574 of 5 stars3.51.00.00.03.11.73.8CDNACareDx4.1645 of 5 stars3.32.00.04.22.10.81.9PSNLPersonalis3.9525 of 5 stars2.53.00.04.23.22.50.6VRDNViridian Therapeutics1.5035 of 5 stars4.50.00.00.01.40.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHCOAdaptHealth 3.00Buy$13.4061.45% UpsideCDNACareDx 2.67Moderate Buy$30.3360.07% UpsidePSNLPersonalis 3.00Buy$7.6723.46% UpsideVRDNViridian Therapeutics 2.90Moderate Buy$37.56155.31% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, VRDN, AHCO, and CDNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/12/2025AHCOAdaptHealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $13.005/8/2025AHCOAdaptHealthRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$14.00 ➝ $13.005/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$31.00 ➝ $27.005/7/2025VRDNViridian TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.005/7/2025VRDNViridian TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.005/7/2025VRDNViridian TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $36.005/5/2025CDNACareDxStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.005/5/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHCOAdaptHealth$3.25B0.34$3.76 per share2.21$11.72 per share0.71CDNACareDx$333.79M3.16$1.35 per share14.00$7.06 per share2.68PSNLPersonalis$84.61M6.48N/AN/A$2.87 per share2.16VRDNViridian Therapeutics$300K4,000.63N/AN/A$6.09 per share2.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHCOAdaptHealth$90.42M$0.5714.568.560.972.63%6.96%2.40%8/5/2025 (Estimated)CDNACareDx$52.55M$1.1516.48N/AN/A19.79%21.16%14.25%7/30/2025 (Estimated)PSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)VRDNViridian Therapeutics-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)Latest PSNL, VRDN, AHCO, and CDNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/6/2025Q1 2025VRDNViridian Therapeutics-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million4/30/2025Q1 2025CDNACareDx$0.06$0.09+$0.03-$0.19$84.56 million$84.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHCOAdaptHealthN/AN/AN/AN/AN/ACDNACareDxN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHCOAdaptHealth1.251.291.07CDNACareDxN/A4.113.84PSNLPersonalisN/A6.916.74VRDNViridian Therapeutics0.0519.4919.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHCOAdaptHealth82.67%CDNACareDxN/APSNLPersonalis61.91%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAHCOAdaptHealth1.55%CDNACareDx4.40%PSNLPersonalis3.80%VRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAHCOAdaptHealth10,500134.95 million132.86 millionOptionableCDNACareDx74055.68 million53.23 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableVRDNViridian Therapeutics5081.59 million81.06 millionOptionablePSNL, VRDN, AHCO, and CDNA HeadlinesRecent News About These CompaniesViridian Therapeutics (NASDAQ:VRDN) Shares Down 4.5% - What's Next?June 17, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Price Target from AnalystsJune 17, 2025 | americanbankingnews.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal yearJune 15, 2025 | investing.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 12, 2025 | marketbeat.comViridian Therapeutics: The Song Remains The SameJune 9, 2025 | seekingalpha.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)June 7, 2025 | marketbeat.comViridian Therapeutics to Participate in Upcoming June Investor ConferencesMay 30, 2025 | businesswire.comBank of America Corp DE Grows Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 30, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Increased by Nuveen Asset Management LLCMay 28, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Millennium Management LLCMay 28, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 109,231 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 27, 2025 | marketbeat.comTwo Sigma Investments LP Sells 57,599 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)May 27, 2025 | marketbeat.comVeligrotug improves proptosis, diplopia symptoms in active, chronic thyroid eye diseaseMay 22, 2025 | healio.comViridian Therapeutics’ SWOT analysis: promising TED treatment stock faces key catalystsMay 21, 2025 | investing.comViridian Therapeutics announces positive long-term durability data for veligrotug for the treatment of active thyroid eye diseaseMay 20, 2025 | ophthalmologytimes.comWhy Viridian Therapeutics, Inc.’s (VRDN) Stock Is Down 5.15%May 15, 2025 | aaii.comVeligrotug receives breakthrough therapy designation for thyroid eye diseaseMay 9, 2025 | healio.comViridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)May 7, 2025 | finance.yahoo.comViridian Therapeutics shares fall as Q1 loss narrows, revenue beatsMay 6, 2025 | in.investing.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial ResultsMay 6, 2025 | finance.yahoo.comViridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue EstimatesMay 6, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL, VRDN, AHCO, and CDNA Company DescriptionsAdaptHealth NASDAQ:AHCO$8.30 -0.09 (-1.07%) Closing price 04:00 PM EasternExtended Trading$8.32 +0.02 (+0.19%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs. It also offers wheelchairs, hospital beds, oxygen concentrators, CPAP masks and related supplies, wound care supplies, diabetes management supplies, wheelchair cushion accessories, orthopedic bracing, breast pumps and supplies, walkers, commodes and canes, and nutritional and incontinence supplies. The company services beneficiaries of Medicare, Medicaid, and commercial insurance payors. The company is headquartered in Plymouth Meeting, Pennsylvania.CareDx NASDAQ:CDNA$18.95 -0.09 (-0.47%) Closing price 04:00 PM EasternExtended Trading$19.00 +0.05 (+0.26%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Personalis NASDAQ:PSNL$6.21 -0.21 (-3.27%) Closing price 04:00 PM EasternExtended Trading$6.23 +0.02 (+0.32%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Viridian Therapeutics NASDAQ:VRDN$14.71 -0.01 (-0.07%) Closing price 04:00 PM EasternExtended Trading$14.98 +0.27 (+1.83%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
